Two new trials investigating baricitinib to delay T1D
What’s happening? Earlier today, Eli Lilly and Company announced that they are launching two new clinical trials for baricitinib in type 1 diabetes (T1D). These phase 3 trials will investigate whether the drug can delay T1D onset or progression and will open for recruitment soon. Read on to learn more about the trials, why this […]
Q&A with Patti Columbe: A glimpse into her journey with Vertex’s manufactured islets
Breakthrough T1D had the pleasure of speaking with Patti Columbe, a participant in Vertex’s pivotal trial for the manufactured islet therapy zimislecel (formerly VX-880). Patti has been living with type 1 diabetes (T1D) for nearly 39 years. This is one of the most exciting T1D trials in terms of getting us closer to cures for […]
The inside scoop on the CATT1 clinical trial
Learn about the people making the CATT1 clinical trial happen, the science behind cadisegliatin for type 1 diabetes, and how to get involved.
Study: Patients willing to incur risks for benefits of novel T1D therapies
A new Breakthrough T1D-funded study finds that people with T1D and their caregivers are largely willing to try advanced new T1D therapies.
A new Breakthrough T1D publication is paving the way for beta cell replacement therapies
Breakthrough T1D’s newest publication outlines a roadmap for beta cell replacement therapies for type 1 diabetes.
ADA 2025 Recap: Cures
Breakthrough T1D was in Chicago, IL for ADA 2025. Here we report on the latest advancements in cures for type 1 diabetes.
ADA 2025 Recap: Improving Lives
Improving Lives Breakthrough T1D’s Improving Lives program focuses on devices, insulins, adjunctive therapies, treatments for complications, and psychosocial interventions to improve the health and quality of life of people living with T1D. Adjunctive therapies and complications There was significant focus on GLP-1 receptor agonists (GLP-1RAs) and SGLT inhibitors (SGLTi) in reducing long-term complications and improving […]
Turning negatives into positives: Clearing up clinical trials misconceptions
This Clinical Trials Awareness Day, we’re exploring lessons from clinical trials and debunking clinical trials misconceptions.
Cell therapies in clinical trials: Moving the needle forward
Breakthrough T1D believes that novel cell therapies in the clinical pipeline will transform T1D management, and Project ACT is how we’re going to make them a reality.
From unexpected diagnosis to DIAGNODE-3 participant
Katie Howell was diagnosed with type 1 diabetes last year at age 25. Now, she's the first DIAGNODE-3 trial participant in NYC.
